ReviewWorld journal of transplantation2025
Towards curing type 1 diabetes: Prospects and challenges of allogeneic or xenogeneic donor islet cell transplantation.
Review in World journal of transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes (T1D) is a chronic, lifelong, autoimmune disease that is debilitating and life-threatening to those who suffer from severe hypoglycaemic events or the devastating chronic complications. Exogenous insulin replacement, including the artificial pancreas, is the current mainstay of T1D therapy but cannot prevent the chronic vascular complications of the disease. They are also responsible for contributing to severe iatrogenic hypoglycaemia and impaired hypoglycaemic awareness. β-cell replacement with either pancreas or islet allotransplantation can reverse diabetes leading to better glycaemic control, prevention of hypoglycaemic events and improved quality of life for patients. The limited supply of cadaveric organ donors is a major barrier to this therapeutic option. Thus, alternative sources of islets are being actively explored, mainly human pluripotent stem-cell derived islets and xenogeneic porcine islets. Although these sources harbor their own risks and problems, various novel and innovative solutions are being perseveringly investigated across the globe to overcome these in the hopes that safe islet transplantation may one day be available to all T1D patients suffering from severe hypoglycaemic events. This review will concentrate on pre-clinical and clinical studies, in addition to the latest scientific discoveries relevant to T1D transplantation therapy using allogeneic or xenogeneic donor islet cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.